Logo

Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Share this
Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Shots:

  • Blanver to register- promote- distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina- Bolivia- Chile- Colombia- Ecuador- Paraguay- Peru- and Uruguay. Helsinn to retain rights all international developments including clinical activities & supply of Pracinostat
  • In 2016- MEI Pharma granted global rights of Pracinostat to Helsinn and a right to sub-license it to the third parties. Helsinn granted exclusive licensing rights of Pracinostat for all territories to Menarini excluding the US- Canada- Japan and South America
  • Pracinostat is an oral pan histone deacetylase inhibitor- currently being evaluated in P-III study in combination with Azacitidine for patients newly diagnosed with AML who are unfit for intensive induction CT and has received FDA’s BT designation for the same indication

Click here to­ read full press release/ article | Ref: Helsinn | Image: Twitter


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions